Safety of Antihypertensive Medication for the Management of Non‐Severe Gestational Hypertension Among Pregnant Individuals in Botswana—Emulating a Series of Target Trials
In this retrospective cohort study, antihypertensive medication initiation between 24 and 35 weeks' gestation for non-severe gestational hypertension was not associated with increased risk of adverse birth outcomes.
Authors
- Rebecca Zash (ORCID: https://orcid.org/0000-0001-5707-421X)
- Mompati Mmalane
- Katherine M. Johnson (ORCID: https://orcid.org/0000-0002-5127-8139)
- Denise L. Jacobson (ORCID: https://orcid.org/0000-0002-5896-7148)
- Judith Mabuta
- Roger Shapiro (ORCID: https://orcid.org/0000-0002-4832-6275)
- Shahin Lockman (ORCID: https://orcid.org/0000-0002-5384-9716)
- Ellen C. Caniglia (ORCID: https://orcid.org/0000-0001-8667-6471)
- Joseph Makhema (ORCID: https://orcid.org/0000-0003-0017-2438)
- Modiegi Diseko
- Julia D. DiTosto (ORCID: https://orcid.org/0000-0002-1600-8328)
- Sunni L. Mumford (ORCID: https://orcid.org/0000-0003-0133-3176)
- Gloria Mayondi (ORCID: https://orcid.org/0000-0003-4557-3075)
Institutions
- Brigham and Women's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- University of Massachusetts Chan Medical School (US)
- Cancer Research And Biostatistics (US)
- Botswana Harvard AIDS Institute Partnership (BW)
- University of Pennsylvania (US)
Publication Details
- Journal
- Paediatric and Perinatal Epidemiology
- Published
- 2025-10-21
- DOI
- https://doi.org/10.1111/ppe.70079
- Citations
- 1
- Primary Topic
- Pregnancy and preeclampsia studies
- Type
- article
- Field-Weighted Citation Impact
- 2.06
Funders
- National Institute of Allergy and Infectious Diseases
- National Institute of Child Health and Human Development
- Eunice Kennedy Shriver National Institute of Child Health and Human Development